PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Poster Psoriasis
P 37
MK-3222, an anti-IL23p19 antibody, is safe and effective in the treatment of
psoriasis
Tamara Kopp 1
Elisabeth Riedl 2
Christine Bangert 1
Eli Greisenegger 1
Ann Horowitz 3
Thomas Marbury 4
Robert Stonerock 4
Victor Vidals 5
Jonathan Dosik 6
Claus Zachariae 7
Norbert Reider 8
Alan J Kivitz 9
Danlin Xu 3
Xiaoli Shirley Hou 3
A.S. Zandvliet 3
Matias Morrison 3
Sauzanne Khalilieh 3
1 Department of Dermatology, Division of Immunology, Allergy & Infectious Diseases,
University of Vienna Medical School, Vienna, Austria
2 Department of Dermatology, Division of General Dermatology, University of Vienna
Medical School, Vienna, Austria
3 Merck& Co., Inc., White House Station NJ, USA
4 Orlando Clinical Research Center, Orlando, FL, USA
5 PRA Lenexa, Kansas, USA
6 TKL Research, Inc. Paramus, NJ, USA
7 Department of Dermatology, Gentofte Hospital, University of Copenhagen, Denmark
8 Deptartment of Dermatology, Medical University of Innsbruck, Innsbruck, Austria
9 Altoona Center for Clinical Research Duncansville, PA, USA
Introduction & Objectives: Psoriasis is a chronic inflammatory skin disorder affecting
approximately 2% of people worldwide. The goal of therapy is clearance of psoriatic
plaques. The benchmark response in most clinical trials is a 75% or greater reduction
from the baseline PASI score. Recent discoveries have demonstrated that IL-23dependent
Th17 cells control much of the inflammatory injury that is observed in
diseases such as psoriasis. The safety and efficacy of the anti-IL23p19 antibody,
MK-3222, was assessed in psoriasis.
Materials & Methods: This was a randomized, double-blind, placebo-controlled,
parallel-group dose-ranging, 3-Part, study which evaluated the safety, tolerability,
91